FDA approves first at-home agitation drug - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves first at-home agitation drug

  • By

  • Mouj Hijazi

  • November 17, 2026

  • 2 min

Share

Clinical Scorecard: FDA approves at-home dexmedetomidine for acute agitation

At a Glance

CategoryDetail
ConditionAcute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder
Key MechanismsDexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist.
Target PopulationAdults with acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder
Care SettingAt-home self-administration during agitation episodes; dexmedetomidine was previously approved for use under health care provider supervision.

Key Highlights

  • The FDA approved dexmedetomidine (Igalmi) sublingual film for at-home treatment of acute agitation in the specified adult populations.
  • The approval was supported by SERENITY At-Home, a phase 3 randomized, double-blind, placebo-controlled safety and tolerability trial.
  • The trial included 208 treated adults and 2,437 agitation episodes across both treatment groups.
  • The trial was not powered to assess efficacy, although the study poster reported higher rates of complete agitation resolution with dexmedetomidine than placebo.
  • Reported safety concerns include hypotension, orthostatic hypotension, and bradycardia.

Guideline-Based Recommendations

Diagnosis

    Management

    • The FDA approved dexmedetomidine sublingual film for at-home treatment of acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults.

    Monitoring & Follow-up

      Risks

      • The source identifies hypotension, orthostatic hypotension, and bradycardia as safety concerns, and lists cardiovascular conditions, history of syncope, hepatic impairment, and concomitant sedating medications as relevant precautions.
      • In SERENITY At-Home, somnolence, including fatigue, was reported after the first treated episode in 22.5% of dexmedetomidine recipients and 17% of placebo recipients; dry mouth in 6.9% and 0.9%, respectively; and dizziness in 4.9% and 0.9%, respectively.

      Patient & Prescribing Data

      Adults with acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.

      The at-home indication is for self-administration during agitation episodes. In the 12-week trial, tolerability was reported as consistent during repeat dosing; no dexmedetomidine recipients discontinued because of adverse events.

      Clinical Best Practices

        Related Resources & Content

        Original Source(s)

        Related Content